Neurol. pro Praxi, 2004; 5: 285-290

Nejčastější chyby a omyly v diagnostice a terapii myasthenia gravis

MUDr. Jiří Piťha1, prof. MUDr. Zdeněk Ambler DrSc2
1 Neurologická klinika 3. LF UK a FN KV, Praha
2 Neonatologické oddělení, FN a LF UK, Plzeň

Keywords: myasthenia gravis, diagnostika, terapie, nesprávné diagnostické a léčebné postupy.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J, Ambler Z. Nejčastější chyby a omyly v diagnostice a terapii myasthenia gravis. Neurol. praxi. 2004;7(5):285-290.

Článek pojednává o možnostech diagnostiky a moderní terapie myasthenia gravis. Vychází z dlouholetých zkušeností autorů. Upozorňuje na nejčastější chyby, ke kterým dochází při stanovení diagnózy. Myasthenia gravis je v současné době relativně dobře léčitelným onemocněním, pokud se respektují zásady správně vedené léčby. Řada omylů je spojena s nevhodným dávkováním, nerespektováním nežádoucích účinků farmak a volbou nesprávných léčebných postupů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ambler Z. Význam elektromyografie v neurologii. In: kolektiv autorů. Neurologie 2003. 1. vydání. Praha: Triton; 2003: 134-159.
    2. Andrews PI. A treatment algorithm for autoimmune myasthenia gravis in childhood. Ann N Y Acad Sci 1998; 841: 789-802. Go to original source... Go to PubMed...
    3. Antonini G, Morino S, Gragnani F, et al. Myasthenia gravis in the erderly: a hospital based study. Acta neurol Scand 1996; 93: 260-262. Go to original source... Go to PubMed...
    4. Berrouschot J, Baumann I, Kalischewski P, et al. Therapy of myasthenic crisis. Crit care Med 1997; 25 (7): 1228-1235. Go to original source... Go to PubMed...
    5. Grob D, Simpson D, Mitsumoto H, et al. Treatment of myasthenia gravis by immunoadsorbtion of plasma. Neurology 1995; 45: 338-344. Go to original source... Go to PubMed...
    6. Gronseth GS, Barohn RJ. Thymectomy for non - thymomatous autoimmune myasthenia gravis (an evidence - based review). Neurology 2000; 55: 7-15. Go to original source... Go to PubMed...
    7. Hohlfeld R, Toyka K, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long - term azathioprine. Ann Neurol 1985; 17: 238-242. Go to original source... Go to PubMed...
    8. Hohfeld R, Wekerle H. The immunopatogenesis of myasthenia gravis. In: Engel AG. Myasthenia gravis and myastenic disorders. Oxford University Press; 1999: 87-110.
    9. Oosterhuis HJGH. Treatment of myasthenia gravis In: Oosterhuis HJGH: Myasthenia gravis, Groningen, Nerological Press, 1997: 68-99. Go to original source...
    10. Palace J, Newsom-Davis J, Lecky B, et al. A randomised duble - blind trial of prednisone alone or with azathioprine in myasthenia gravis. Neurology 1980; 50: 1778-1783. Go to original source... Go to PubMed...
    11. Pascuzzi RM, Duane DD, Lambert EH, et al. Long - term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298. Go to original source... Go to PubMed...
    12. Piťha J, Ambler Z. Myasthenia gravis. In: kolektiv autorů. Neurologie 2003. 1. vydání. Praha: Triton; 2003: 188-202.
    13. Sanders DB. Generalised myasthenia gravis: Clinical presentation and diagnosis. In: Kaminski HJ. Myasthenia gravis: Diagnosis and Treatment. Education program syllabus American Academy of Neurology. 56th Anual Meeting. San Franscisco: 2004: 10-17.
    14. Somner N, Sigg B, Melms A, et al. Ocular myasthenia gravis: responze to long term immunosupresive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156-62. Go to original source... Go to PubMed...
    15. Spring PJ, Spies JM. Myasthenia gravis. Options and timing of immunomodulatory treatment. Bio Drugs 2001; 15 (3): 173-183. Go to original source...
    16. Trontelj JV, Sanders DB, Stĺlberg EV. Electrophysiological methods for assessing neuromuscular transmission. In: Brown WF, Bolton CF, Aminoff MJ, editors. Neuromuscular Function and Disease. Philadelphia: W.B. Saunders, 2002: 414-432.
    17. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002; 26 (4): 549-52. Go to original source... Go to PubMed...
    18. Yeh JH, Chiu HC. Plasmapheresis in myasthenia gravis: a comparative study od daily versus alternately daily schedule. Acta Neurol Scand 1999; 99 (3): 147-151. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.